Shares of Granules India rose 1% in the morning trade on the BSE. The US Food & Drug Administration (USFDA) has approved the Abbreviated New Drug Application (ANDA) filed by Granules Pharmaceuticals, Inc., a wholly-owned foreign subsidiary of Granules India Limited for Amphetamine Sulfate Tablets USP 5 mg and 10 mg.
It is bioequivalent to the reference listed drug product (RLD), Evekeo Tablets, 5 mg and 10 mg, of Arbor Pharmaceuticals, LLC, the company said in the press note.
Amphetamine Sulfate tablets is a central nervous system stimulant used to treat a sleep disorder, increase attention, decrease impulsiveness and hyperactivity in patients with Attention Deficit Hyperactivity Disorder (ADHD).
Granules India Ltd is currently trading at Rs90.85, up by Rs1.25 or 1.4% from its previous closing of Rs89.60 on the BSE.
The scrip opened at Rs90 and has touched a high and low of Rs92 and Rs89.15 respectively.